Literature DB >> 17943265

[Developments and perspectives in radioablative techniques].

T F Jakobs1, R-T Hoffmann, K Tatsch, C Trumm, M F Reiser, T K Helmberger.   

Abstract

The encouraging preliminary results of radioembolization therapy in hepatocellular carcinoma and liver metastases from colorectal cancer have suggested that this mode of therapy could also be successful in breast and neuroendocrine metastases from colorectal cancer. (90)Yttrium microspheres in combination with radiosensitizing agents and growth factor inhibitors present opportunities to evaluate its application in combinatorial treatment paradigms with modern chemotherapy regimens. Other randomized trials are needed in hepatocellular carcinoma, to compare radioembolization with (90)yttrium against transarterial chemoembolization, bland embolization, drug-eluting beads, and best supportive care. A further potential research area besides the application of radioembolization for extrahepatic tumors is the determination of quality of life in randomized studies comparing radioembolization with systemic chemotherapy regimens with or without percutaneous radiation therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17943265     DOI: 10.1007/s00117-007-1572-y

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.803


  34 in total

1.  Intrahepatic (90)Y-microspheres for hepatocellular carcinoma.

Authors:  S Ho; J W Lau; T W Leung
Journal:  J Nucl Med       Date:  2001-10       Impact factor: 10.057

Review 2.  The concurrent chemoradiation paradigm--general principles.

Authors:  Tanguy Y Seiwert; Joseph K Salama; Everett E Vokes
Journal:  Nat Clin Pract Oncol       Date:  2007-02

3.  Cutaneous radiation necrosis as a complication of yttrium-90 synovectomy.

Authors:  Sally Sojan; Dylan Bartholomeusz
Journal:  Hell J Nucl Med       Date:  2005 Jan-Apr       Impact factor: 1.102

4.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

5.  Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.

Authors:  George P Stathopoulos; Sotiris K Rigatos; John G Stathopoulos; John P Xynotroulas; Evangelini Dimou
Journal:  Am J Clin Oncol       Date:  2005-12       Impact factor: 2.339

6.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

7.  90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival.

Authors:  Affaan K Bangash; Bassel Atassi; Virginia Kaklamani; Thomas K Rhee; Maurice Yu; Robert J Lewandowski; Kent T Sato; Robert K Ryu; Vanessa L Gates; Steven Newman; Robert Mandal; William Gradishar; Reed A Omary; Riad Salem
Journal:  J Vasc Interv Radiol       Date:  2007-05       Impact factor: 3.464

8.  Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.

Authors:  Ricky A Sharma; Guy A Van Hazel; Bruno Morgan; David P Berry; Keith Blanshard; David Price; Geoffrey Bower; Jennifer A Shannon; Peter Gibbs; William P Steward
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

9.  Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis.

Authors:  Riad Salem; Robert Lewandowski; Carol Roberts; James Goin; Kenneth Thurston; Marwan Abouljoud; Angi Courtney
Journal:  J Vasc Interv Radiol       Date:  2004-04       Impact factor: 3.464

10.  Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer.

Authors:  Douglas M Coldwell; Andrew S Kennedy; Charles W Nutting
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-05-24       Impact factor: 7.038

View more
  5 in total

1.  Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients.

Authors:  K J Paprottka; F Schoeppe; M Ingrisch; J Rübenthaler; N N Sommer; E De Toni; H Ilhan; M Zacherl; A Todica; P M Paprottka
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-14       Impact factor: 9.236

2.  Robust evidence for long-term survival with 90Y radioembolization in chemorefractory liver-predominant metastatic colorectal cancer.

Authors:  T F Jakobs; K J Paprottka; F Raeßler; F Strobl; S Lehner; H Ilhan; C G Trumm; W P Fendler; W Sommer; P M Paprottka
Journal:  Eur Radiol       Date:  2016-04-08       Impact factor: 5.315

3.  [Metastases of colorectal carcinoma].

Authors:  S Clasen; H Rempp; P L Pereira
Journal:  Radiologe       Date:  2008-11       Impact factor: 0.635

4.  Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy.

Authors:  Yvonne Nadine Fahmueller; Dorothea Nagel; Ralf-Thorsten Hoffmann; Klaus Tatsch; Tobias Jakobs; Petra Stieber; Stefan Holdenrieder
Journal:  BMC Cancer       Date:  2012-01-04       Impact factor: 4.430

5.  Trans-arterial chemoperfusion for the treatment of liver metastases of breast cancer and colorectal cancer: Clinical results in palliative care patients.

Authors:  Tatjana Gruber-Rouh; Marcel Langenbach; Nagy N N Naguib; Nour-Eldin M Nour-Eldin; Thomas J Vogl; Stephan Zangos; Martin Beeres
Journal:  World J Clin Oncol       Date:  2017-08-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.